Sanofi and Boehringer announce job cuts in France

By PharmaCompass

2018-12-13

Impressions: 120 Article

Last week, we had carried news on German drug major Bayer, which has drawn out a revamp plan that includes plans to slash 12,000 jobs worldwide and restructuring of its R&D business.

This week, there is more bad news from the pharma industry job market. French drugmaker Sanofi told unions last week it was planning to cut 670 jobs in France.

A Sanofi spokesman confirmed the company’s intention to shed 670 jobs out of a 25,000 workforce in France and said the plan was to be completed by the end of 2020. The plan, which is to be set on a voluntary basis, would affect human resources, IT, and finances among others. In addition, 80 IT jobs are to be outsourced.

Sanofi will also invest US$ 794 million (Euro 700 million) in France to upgrade its production sites, notably in the areas of vaccines manufacturing and other biologic medicines.

There were more job cuts announced in France. Boehringer Ingelheim is cutting around 10 percent of its workforce in France under a reorganization of its activities in the country. The overhaul will see 197 jobs lost in the company’s human health division, with a further 130 eliminated from its animal health segment. However, the company indicated that the reorganization will also result in the creation of 32 new jobs. The plan additionally includes some modification for 180 employment contracts of sales representatives, including 120 employees in the company's French human health division.

The PharmaCompass Newsletter – Sign Up, Stay Ahead

Feedback, help us to improve. Click here

Image Credit : #Phisper Infographic by SCORR MARKETING & PharmaCompass is licensed under CC BY 2.0

“ The article is based on the information available in public and which the author believes to be true. The author is not disseminating any information, which the author believes or knows, is confidential or in conflict with the privacy of any person. The views expressed or information supplied through this article is mere opinion and observation of the author. The author does not intend to defame, insult or, cause loss or damage to anyone, in any manner, through this article.”

NEWS

DRUGS & DEVELOPMENTS

MARKET INTEL by PharmaCompass